Solstice Medicine CO is categorized under Patent Medicines in Los Angeles, CA and active since 2001.
Solstice Medicine CO was established in 2001, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Patent Medicines business, which does work in the B2B market, and is classified as a Patent Medicines, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Phillip So, Owner at the company’s single location by writing to 215 West Ann St, Los Angeles, California CA 90012 or by phoning (323) 221-8181. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Solstice Medicine CO |
| Contact Person: | Phillip So, Owner |
| Address: | 215 West Ann St, Los Angeles, California 90012 |
| Phone Number: | (323) 221-8181 |
| Website Address: | solsticemed.com |
| Annual Revenue (USD): | $2.500.000 to $4.999.999 |
| Founded: | 2001 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Patent Medicines |
| SIC Code: | 5122 |
| NAICS Code: | 6211110 |
| Share This Business: |
Solstice Medicine CO was started in 2001 to provide professional Patent Medicines under the SIC code 5122 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.
Feel free to contact Phillip So, Owner for inquiries that concern Solstice Medicine CO by calling the company number (323) 221-8181, as your correspondence is most welcome. Additionally, the physical location of the single location of Solstice Medicine CO can be found at the coordinates 34.06606,-118.23233 as well as the street address 215 West Ann St in Los Angeles, California 90012.
For its online presence, you may visit Solstice Medicine CO’s website at solsticemed.com and engage with its social media outlets through on Twitter and on Facebook.